SWK Holdings

Impedimed Limited is a medical software technology company based in Pinkenba, Australia, specializing in the development, manufacturing, and distribution of bioimpedance spectroscopy (BIS) devices and software services. The company offers a range of noninvasive devices, including SOZO, which is designed for detecting lymphedema and monitoring fluid status in heart failure patients, as well as SFB7, which analyzes body composition in healthy individuals. Additionally, ImpediMed provides ImpediVET, a BIS device tailored for veterinary applications. The company's products cater primarily to hospitals and clinics across Australia, North America, and other international markets. Founded in 1999, Impedimed is committed to advancing medical technology for clinical assessments and monitoring of fluid status and tissue composition, while also offering a cloud-based platform for managing patient data.

Journey Medical Corporation is a commercial stage pharmaceutical company dedicated to the development, acquisition, licensing, and commercialization of branded dermatology products. As a subsidiary of Fortress Biotech, Journey Medical has successfully launched four innovative products since 2016 and currently markets a portfolio that includes eight branded drugs and three authorized generic prescription medications, all designed to treat various dermatological conditions. Key products in its lineup include Qbrexza, Accutane, Amzeeq, and Exelderm, which address a range of skin-related ailments. The company's focus on dermatology positions it as a key player in the pharmaceutical industry, catering to specific needs within this therapeutic area.

Shield Therapeutics is an independent specialty pharmaceutical company based in Wollerau, Switzerland, concentrating on the development and commercialization of late-stage, mineral-derived pharmaceuticals aimed at addressing significant unmet medical needs. The company’s primary focus is on its lead product, Feraccru, which is designed for the treatment of iron deficiency anemia associated with inflammatory bowel disease, as well as chronic kidney disease. Additionally, Shield Therapeutics is advancing PT20, a product intended for the management of hyperphosphatemia, which is nearing the final stages of development. The company generates most of its revenue from the Feraccru segment.

Elutia is a commercial-stage regenerative medicine company dedicated to advancing surgical outcomes for patients receiving implantable medical devices. The company focuses on developing a new generation of differentiated products through its proprietary tissue processing platforms, resulting in a portfolio of advanced regenerative medical products that closely mimic natural biological materials. Elutia operates across several segments, including Device Protection, Women's Health, and Cardiovascular, with the Women's Health segment generating the majority of its revenue. Its products aim to address unmet clinical needs by promoting healthy tissue formation and reducing complications associated with medical device implants, such as scar-tissue formation and capsular contraction.

MedMinder Systems, Inc. is a company that specializes in developing innovative solutions for medication management and adherence support. Founded in 2007 and headquartered in Needham, Massachusetts, the company offers a range of products including automatic pill dispensers that remind users of their medication schedules through visual and auditory alerts, as well as notifications sent to caregivers and pharmacists. MedMinder's offerings include various types of pill dispensers, locked dispensers, medical alert products, and pre-filled medication trays. The company serves a diverse customer base across several states, including Massachusetts, New York, Florida, and others. Through its services, MedMinder aims to simplify the process of taking medications, thereby improving adherence and enhancing patient care.

Advanced Oxygen Therapy specializes in the development and provision of Advanced Wound Care products that incorporate its patented non-invasive Topical Wound Oxygen (TWO2) therapy. This innovative approach is designed to treat a variety of wound types, with particular efficacy in addressing chronic wounds such as diabetic, pressure, and venous ulcers, as well as acute wounds including post-surgical, cosmetic, and burn injuries. TWO2 therapy works by reversing tissue hypoxia, stimulating cellular mechanisms for tissue regeneration, reducing edema through non-contact sequential compression, and creating an environment that eliminates pathogens and combats infection. By effectively closing previously unresponsive wounds, Advanced Oxygen Therapy's solutions play a crucial role in saving limbs, lowering healthcare costs, and significantly enhancing patients' quality of life. The company offers its topical wound oxygen solutions for both institutional and home care settings, ensuring improved health and independence for patients globally.

Acer Therapeutics Inc. is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Founded in 2013 and headquartered in Newton, Massachusetts, the company has a diverse clinical pipeline that includes several promising candidates. EDSIVO is designed for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation. ACER-001, a taste-masked formulation of sodium phenylbutyrate, targets various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. Additionally, Acer is developing osanetant for the treatment of induced vasomotor symptoms and has initiated research on emetine hydrochloride as a potential COVID-19 treatment in collaboration with the National Center for Advancing Translational Sciences. The company also holds a license agreement with Sanofi for worldwide rights to osanetant.

MolecuLight specializes in innovative imaging solutions for wound care, focusing on the detection of harmful bacteria and accurate wound measurement. The company develops portable handheld optical imaging devices that allow medical practitioners to visualize bacteria and assess wound status directly at the point of care. These devices facilitate the analysis and visual detection of bacteria, provide procedural guidance, and enable the assessment of viable and nonviable tissue. By offering these capabilities, MolecuLight supports healthcare professionals in selecting appropriate therapies for their patients and effectively monitoring wound healing progress.

Trio Healthcare International is a manufacturer based in Skipton, United Kingdom, specializing in medical solutions for the healthcare and veterinary markets. Established in 2006, the company develops and supplies a range of products primarily focused on ostomy, wound care, and continence management. Trio Healthcare's offerings include silicone-based ostomy accessories such as seals, sprays, wipes, gels, and flanges, designed to enhance patient comfort and protect skin integrity for stoma patients. Additionally, the company provides veterinary solutions aimed at animal owners and veterinary professionals, contributing to improved care in both human and animal health sectors.

4WEB Medical, founded in 2008 and based in Frisco, Texas, specializes in the development and manufacture of 3D-printed titanium implant devices for the healthcare sector. Led by President and CEO Jessee Hunt, the company leverages a unique geometry known as the "4WEB," derived from extensive research in topological dimension theory, to create high-strength, lightweight web structures used in orthopedic implants. The 4WEB geometry optimizes engineering principles such as truss design and load transfer, resulting in implants that enhance the healing process through improved osseous incorporation. Initially focused on the spine implant market, 4WEB Medical has expanded its technology to offer a diverse range of products for various orthopedic applications, including solutions for foot and ankle procedures. The company's implant portfolio provides comprehensive surgical options for neurosurgeons and orthopedic surgeons, emphasizing superior strength, optimal porosity, and structural support.

Epica International, Inc. specializes in designing, developing, and distributing innovative robotic systems that integrate advanced imaging technology and precision robotics. The company offers a range of products, including Vimago, a CT imaging and fluoroscopy device for veterinary diagnostics; Pegaso, a high-definition CT system for equine applications; and Artemis, a device for non-invasive regenerative therapy. Additionally, Epica provides Ortis, a robotic system for orthopedic carving, SandRob for surface processing needs, ScultoRob for milling artistic designs, and ARPP, a software for robotic simulation and control. Established in 2013 and headquartered in San Clemente, California, Epica serves various markets, including veterinary medicine, orthotics and prosthetics, and surface processing, aiming to enhance treatment outcomes through the integration of imaging and robotics.

Parnell Living Science, established in 1968 and headquartered in Sydney, Australia, specializes in veterinary pharmaceuticals. The company offers a range of products for companion, performance, and production animals, focusing on therapeutic areas such as osteoarthritis treatment and protection, anti-inflammatories, minerals, reproduction, clinic essentials, and anti-infectives. Notable products include GLYDE, a nutraceutical for canine osteoarthritis management, and disease modifying osteoarthritis drugs. Parnell serves primarily the pastoral industry in Australia and has expanded its operations globally to the United States, Canada, Middle East, and Asia-Pacific. The company is committed to developing innovative animal health solutions, with several new products planned for release over the next five years, particularly targeting the companion animal sector.

SynCardia Systems, Inc. is a medical technology company based in Tucson, Arizona, founded in 2001. The company specializes in the development, manufacturing, and commercialization of the SynCardia temporary Total Artificial Heart (TAH-t), an implantable device designed to fully replace the function of a failing heart in patients with advanced heart failure. The SynCardia TAH-t serves as a critical bridge to transplant, enabling patients to survive while awaiting a matching donor heart. SynCardia operates in the United States, European Union, and Canada, focusing on improving outcomes for individuals with severe cardiac conditions.

KANA Software, Inc., a wholly owned subsidiary of Verint, specializes in providing Customer Engagement Optimization solutions tailored for Fortune 500 companies, mid-market businesses, and government agencies. The company offers three primary product lines: KANA Enterprise, which unifies agent and customer experiences across multiple channels and integrates legacy systems; LAGAN Enterprise, designed to address the complex data management needs of the public sector, including non-emergency call centers; and KANA Express, a cloud-based solution that delivers integrated multi-channel customer service for mid-size businesses and government entities. All product offerings feature capabilities such as a unified agent desktop, integrated knowledge management, email and live chat management, web self-service, social media management, and comprehensive reporting and analytics, ensuring a seamless interaction experience for both agents and customers.

eVergance Partners provides customer relationship management strategy, transformation, and implementation consulting services.